| Endothelial dysfunction precedes atherosclerosis in systemic sclerosis—relevance for prevention of vascular complications G Szűcs, O Tímár, Z Szekanecz, H Der, G Kerekes, S Szamosi, ... Rheumatology 46 (5), 759-762, 2007 | 174 | 2007 |
| Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study J Avouac, UA Walker, E Hachulla, G Riemekasten, G Cuomo, PE Carreira, ... Annals of the rheumatic diseases 75 (1), 103-109, 2016 | 152 | 2016 |
| Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases Z Szekanecz, IB McInnes, G Schett, S Szamosi, S Benkő, G Szűcs Nature Reviews Rheumatology 17 (10), 585-595, 2021 | 128 | 2021 |
| Phenotypes determined by cluster analysis and their survival in the prospective European scleroderma trials and research cohort of patients with systemic sclerosis V Sobanski, J Giovannelli, Y Allanore, G Riemekasten, P Airò, S Vettori, ... Arthritis & rheumatology 71 (9), 1553-1570, 2019 | 92 | 2019 |
| The NLRP3 inflammasome-interleukin 1 pathway as a therapeutic target in gout Z Szekanecz, S Szamosi, GE Kovács, E Kocsis, S Benkő Archives of biochemistry and biophysics 670, 82-93, 2019 | 82 | 2019 |
| Increased arterial stiffness as the marker of vascular involvement in systemic sclerosis O Timar, P Soltesz, S Szamosi, H Der, S Szanto, Z Szekanecz, G Szuecs The Journal of rheumatology 35 (7), 1329-1333, 2008 | 80 | 2008 |
| Malignancies associated with systemic sclerosis É Szekanecz, S Szamosi, Á Horváth, Á Németh, B Juhász, J Szántó, ... Autoimmunity reviews 11 (12), 852-855, 2012 | 77 | 2012 |
| Systemic sclerosis–rheumatoid arthritis overlap syndrome: a unique combination of features suggests a distinct genetic, serological and clinical entity G Szücs, Z Szekanecz, E Zilahi, A Kapitány, S Baráth, S Szamosi, ... Oxford University Press 46 (6), 989-993, 2007 | 76 | 2007 |
| Effects of 1-year anti-TNF-α therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis K Gulyás, Á Horváth, E Végh, A Pusztai, Á Szentpétery, Z Pethö, A Váncsa, ... Clinical rheumatology 39, 167-175, 2020 | 71 | 2020 |
| Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices É Szekanecz, G Szűcs, Z Szekanecz, T Tarr, P Antal-Szalmás, S Szamosi, ... Journal of autoimmunity 31 (4), 372-376, 2008 | 68 | 2008 |
| Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept É Rákóczi, B Perge, E Végh, P Csomor, A Pusztai, S Szamosi, N Bodnár, ... Joint Bone Spine 83 (6), 675-679, 2016 | 55 | 2016 |
| Effects of adalimumab treatment on vascular disease associated with early rheumatoid arthritis G Kerekes, P Soltesz, G Szucs, S Szamosi, H Der, Z Szabo, L Csathy, ... IMAJ-Israel Medical Association Journal 13 (3), 147, 2011 | 55 | 2011 |
| Gastrointestinal manifestations in Hungarian scleroderma patients S Szamosi, Z Szekanecz, G Szűcs Rheumatology international 26 (12), 1120-1124, 2006 | 52 | 2006 |
| Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis-a prospective case … O Timár, Z Szekanecz, G Kerekes, J Végh, AV Oláh, G Nagy, Z Csiki, ... Arthritis research & therapy 15, 1-9, 2013 | 51 | 2013 |
| Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B … A Váncsa, Z Szabó, S Szamosi, N Bodnár, E Végh, L Gergely, G Szűcs, ... The Journal of rheumatology 40 (5), 565-571, 2013 | 46 | 2013 |
| Pharmacogenetics of etanercept in rheumatoid arthritis MI Danila, LB Hughes, SL Bridges Future Medicine Ltd 9 (8), 1011-1015, 2008 | 46 | 2008 |
| Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol … L Hartman, LA Rasch, T Klausch, HWJ Bijlsma, R Christensen, ... Trials 19, 1-12, 2018 | 43 | 2018 |
| Biologics—beyond the joints Z Szekanecz, S Szántó, Z Szabó, A Váncsa, S Szamosi, N Bodnár, ... Autoimmunity Reviews 9 (12), 820-824, 2010 | 42 | 2010 |
| Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study VK Jaeger, M Tikly, D Xu, E Siegert, E Hachulla, P Airò, G Valentini, ... Rheumatology 59 (7), 1684-1694, 2020 | 39 | 2020 |
| Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis E Végh, G Kerekes, A Pusztai, A Hamar, S Szamosi, A Váncsa, L Bodoki, ... Rheumatology international 40, 427-436, 2020 | 39 | 2020 |
